Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

GlobeNewswire May 25, 2021

ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development

GlobeNewswire May 21, 2021

ProMIS Neurosciences (TSX:PMN) appoints Neil Warma to Board of Directors

Trevor Abes  May 19, 2021

ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors

GlobeNewswire May 19, 2021

ProMIS Neurosciences Announces First Quarter 2021 Results

GlobeNewswire May 14, 2021

ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board

GlobeNewswire May 12, 2021

ProMIS Neurosciences Announces Fiscal Year 2020 Results

GlobeNewswire March 31, 2021

IIROC Trade Resumption - PMN

Canada NewsWire March 22, 2021

IIROC Trading Halt - PMN

Canada NewsWire March 22, 2021

ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

GlobeNewswire March 22, 2021

ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer's/Amyloid Field

GlobeNewswire February 2, 2021

ProMIS Neurosciences Announces Strategic Priorities for 2021

GlobeNewswire January 12, 2021

ProMIS Neurosciences Completes Offering of Special Warrants

GlobeNewswire November 16, 2020

ProMIS Neurosciences Announces Third Quarter 2020 Results

GlobeNewswire November 11, 2020

ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer's disease

GlobeNewswire November 9, 2020

ProMIS Neurosciences Closes First Tranche of Private Placement

GlobeNewswire November 5, 2020

ProMIS Neurosciences' Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium

GlobeNewswire October 30, 2020

ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board

GlobeNewswire October 29, 2020

ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants

GlobeNewswire October 23, 2020

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

GlobeNewswire October 21, 2020